



VILLA DONATELLO
CLINICA APERTA

I SIMPOSI SULLA SALUTE
DI VILLA DONATELLO

INCONTRI MENSILI PER L'AGGIORNAMENTO MEDICO SU PROCEDURE
DI PREVENZIONE, DIAGNOSI E TERAPIA DELLE PIÙ FREQUENTI
MALATTIE METABOLICHE, CARDIOVASCOLARI ED ONCOLOGICHE.

Venerdì 21 Febbraio 2020

COME CURARE OGGI IL CANCRO DEL COLON DESTRO

MODERATORI

Francesco Di Costanzo (Firenze), Teresita Mazzei (Firenze), Renato Morani (Firenze)

3 crediti ECM

ore 17.00 **LA MORFOLOGIA E LA STADIAZIONE**

Luca Messerini (Firenze)

ore 17.15 **LA DIAGNOSI MOLECOLARE**

Michelangelo Fiorentino (Bologna)

ore 17.30 **I FATTORI PROGNOSTICI**

Giandomenico Roviello (Firenze)

ore 17.45 **LA RESEZIONE ENDOSCOPICA DEL POLIPO CON CARCINOMA INVASIVO**

Riccardo Naspetti (Firenze)

ore 18.00 **L'ESCISSIONE COMPLETA DEL MESOCOLON**

Francesco Tonelli (Firenze)

ore 18.15 **LA TECNICA MINI-INVASIVA**

Andrea Coratti (Firenze)

ore 18.30 **LA TERAPIA COMPLEMENTARE ADIUVANTE**

Enrico Mini (Firenze)

ore 18.45 **LA TERAPIA ONCOLOGICA NEL CARCINOMA AVANZATO**

Lorenzo Antonuzzo (Firenze)

ore 19.00 **DISCUSSIONE**

ore 19.30 **CONCLUSIONI**

ore 19.45 **COMPILAZIONE QUESTIONARIO ECM**

ore 20.00 **CHIUSURA LAVORI**



FONDAZIONE
BACCIONI
BORGHESI

Per informazioni ed iscrizioni:

Segreteria Organizzativa: EXPOS Srl - seminari@fondazionefirmo.com - 055 2336663 - Provider ECM: Nico srl

 VILLA DONATELLO

PIÙ SPAZIO ALLA TUA SALUTE

Via Attilio Ragionieri, 101 - Sesto Fiorentino - Zona Firenze Castello - www.villadonatello.it

Con il patrocinio di:




La morfologia e la stadiazione

Luca Messerini



Dipartimento di Medicina Sperimentale e Clinica
Sezione di Chirurgie Specialistiche
e di Diagnostica Istopatologica e Molecolare
Università degli Studi di Firenze



Embriology



Midgut: duodenum (2nd portion), jejunum, ileum, appendix, ascending colon, proximal 2/3 of the transverse colon.

Hindgut: distal 1/3 of the transverse colon, splenic flexure, descending colon, rectum.

Histology

Proximal location: Paneth cells, goblet cells

Distal location: no Paneth cells, >goblet cells



WHO 2018

For practical purposes colorectal carcinomas are divided into three groups by location:

-Right-sided colon carcinoma

(including those in the caecum, ascending colon, hepatic flexure and transverse colon)

-Left-sided colon carcinoma

(located anywhere from the splenic flexure up to the sigmoid)

-Rectal carcinomas

Classification of colorectal carcinoma WHO 2018

- ❖ Adenocarcinoma NOS
- ❖ Serrated adenocarcinoma
- ❖ Adenoma-like adenocarcinoma
- ❖ Micropapillary carcinoma
- ❖ Medullary carcinoma
- ❖ Mucinous adenocarcinoma
- ❖ Signet-ring cell carcinoma
- ❖ Undifferentiated carcinoma
- ❖ Others

Grading

G1 >95% gland formation


G2 50-95% gland formation

G3 >0-49% gland formation


Low-grade: G1-G2

High grade: G3

*Grading is based on the least differentiated component




Adenocarcinoma NOS



Serrated

Adenoma-like

Mucinous




Micropapillary adenocarcinoma 5%

Small clusters of tumor cells within stromal spaces mimicking vascular channels.

Lymph-nodes metastasis, lymphatic, venous and perineural invasion are frequently present.

KRAS, p53




Medullary carcinoma 4%

Sheets of malignant cells with vesicular nuclei, prominent nucleoli, prominent infiltration by lymphocytes. Good prognosis.

Loss of CDX2 and of CK20.

MSI, BRAF-V600E mutation.




Signet-ring cell carcinoma 1%

Signet-ring cells >50% of the tumor cells.

Metastases develop rapidly.

Bad prognosis.

MSI, KRAS, BRAF-V600E mutation




Mucinous adenocarcinoma

>50% of the lesion is composed of pools of extracellular mucin that contain malignant epithelium.

Predilection for right colon.

MSI 40%, KRAS 60%.



Serrated adenocarcinoma

This rare variant has architectural similarity to a sessile serrated polyp with glandular serration that can be accompanied by mucinous areas.

Right colon and rectum.

KRAS 35%, BRAF 45%, MSI 30%.

Adenoma-carcinoma sequence

progressive step-wise accumulation of genetic and epigenetic events







Fig. 1. Carcinogenesis pathway of CRC. The mutation in Adenomatous Polyposis Coli gene, APC, leads to accumulation of cytoplasmic β catenin, which in turn transported to the nucleus to bind Tcf/Lef complex. Then, Tcf/Lef complex activates C-myc resulting in cellular proliferation. The second hit may be caused by KRAS and BRAF gene mutations. This is catastrophic to the cell especially when repair system genes such as MSH, MLH and MUTYH are nonfunctional. Besides, the epigenetic methylation of critical genes such as P53 and PTEN genes drives tumorigenesis. As well, degradation of mRNA by defective miRNAs is also involved in CRC carcinogenesis.


Serrated pathway




**Polipo
iperplastico**



**Adenoma «serrato»
sessile**



**Adenoma «serrato»
tradizionale**






Serrated polyps of the colon and rectum WHO 2010


Hyperplastic polyps	75% of all serrated polyps
Sessile serrated adenomas/polyps	15-25% of all serrated polyps
Traditional serrated adenoma	<1% of all polyps

«The SSA/P was identified as a subgroup that comprised about 20% of what had previously been called HPPs.» KP Batts 2015


Sessile serrated adenoma/polyp







Microvesicular HP(MVHP)



Sessile Serrated Lesion



Traditional serrated adenoma




Goblet-cell rich HP (GCHP)


SSL with dysplasia

Serrated lesions and polyps of the colon and rectum WHO 2018


Polipo iperplastico




Lesione serrata sessile



LSS con displasia



Adenoma serrato tradizionale



< 5mm.

Proximale 20%

Distale 80%

BRAF (MVHP) 60%

KRAS (GCHP) mut+

CIMP +/-

MLH1- NO

5-10 mm.

Proximale 85%

Distale 15%

BRAF 90%

KRAS mut-

CIMP 90%

MLH1- NO

5-12 mm.

Proximale 85%

Distale 15%

BRAF 90%

KRAS mut-

CIMP 90%

MLH1- 75%

10-15mm

Proximale 10%


Distale 90%

BRAF mut+

KRAS mut +

CIMP ++

MLH1- NO




Diagrammatic representation of the serrated neoplasia pathway. Sessile serrated lesions (SSLs) have *BRAF* mutation and can develop de novo or post-polypoid hyperplastic polyps (HPs). A key molecular event thought to precipitate the progression of SSL to malignancy is either *MLH1* methylation or CpG island methylator phenotype (CIMP), progressing to mismatch repair (MMR)-deficient colorectal carcinoma, or *TP53* mutation progressing to adenoma. Traditional serrated adenomas (TSAs) may develop de novo, possibly from SSL or from goblet cell HP (dotted lines). TSAs progress via high-grade dysplasia and MMR-proficient colorectal carcinoma. WNT signalling pathway activation occurs in all pathways through different mechanisms.

Opportunities for immunotherapy in microsatellite instable colorectal cancer

Harm Westdorp^{1,2} · Felix L. Fennemann¹ · Robbert D. A. Weren³ ·
Tanya M. Bisseling⁴ · Marjolijn J. L. Ligtenberg^{3,5} · Carl G. Figdor¹ ·
Gerty Schreiber¹ · Nicoline Hoogerbrugge³ · Florian Wimmers¹ ·
I. Jolanda M. de Vries^{1,2}


Pathologic features of MSI CRCs

- Mucinous differentiation
- Crohn's like peritumoral reaction
- Tumor-infiltrating CD8 lymphocytes
- High yield of lymph-nodes in resected specimens
- Right-sided



Assessment of Colorectal Cancer Molecular Features along Bowel Subsites Challenges the Conception of Distinct Dichotomy of Proximal vs. Distal Colorectum

Mai Yamauchi¹, Teppei Morikawa¹, Aya Kuchiba¹, Yu Imamura¹, Zhi Rong Qian¹, Reiko Nishihara¹, Xiaoyun Liao¹, Levi Waldron^{2,3}, Yujin Hoshida⁴, Curtis Huttenhower², Andrew T. Chan^{5,6}, Edward Giovannucci^{6,7}, Charles S. Fuchs^{1,6}, and Shuji Ogino^{1,8}



→ Frequencies of CIMP/MSI subtypes of colorectal cancer along bowel subsites. The frequency of CIMP-high MSI-high tumors increased gradually from rectum to ascending colon, while that of CIMP-low/0 MSS tumors decreased gradually from rectum to ascending colon.

CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.

Colorectal Cancer

Microsatellite instability (15%-20%)



-**HNPCC** (Lynch syndrome)
germline mutations MMR

-Sporadic CRC

hypermethylation MLH1
BRAF mutations

- Midgut
- Exophytic
- Mucinous
- Worse prognosis

➤ **Serrated pathway**



Chromosomal instability (80%-85%)

-FAP


germline mutations APC

-Sporadic CRC


acquired mutations
APC, KRAS, p53...

- Hindgut
- Infiltrating
- Non-mucinous
- Better prognosis

➤ **Adenoma pathway**



Proximal colon	30-35%
Distal colon	25-30%
Rectum	30-35%



Right-sided colorectal cancer

- Predominantly occur in female
- Occur in older age
- Serrated pathway (MSI)
- Mucinous, Signet- ring cells, G3
- High T cell infiltration
- Metastases in peritoneal region
- Responde well to immunotherapy
- Better prognosis in stage I-II
- Worse prognosis in stage III and IV

Stadiazione del carcinoma del colon-retto AJCC 2017 (TNM)

TX	Tumore primitivo non valutabile	NX	non valutabili
T0	Tumore primitivo non evidente	N0	assenza di metastasi
Tis	Carcinoma in situ (intraepiteliale o intramucoso)	N1	1-3 linfonodi regionali
T1	Tumore che infiltra la sottomucosa	N1a	1 linfonodo regionale
T2	Tumore che infiltra la muscolare propria	N1b	2-3 linfonodi regionali
T3	Tumore che supera la muscolare propria e infiltra la sottosierosa o i tessuti pericolici o perirettali non rivestiti da sierosa	N1c	depositi tumorali in N0 (sottosierosa, mesentere, mesoretto)
T4a	Tumore che invade e perfora il peritoneo viscerale	N2	≥ 4 linfonodi regionali
T4b	Tumore invade direttamente organi adiacenti	N2a	5-6 linfonodi regionali
		N2b	≥ 7 linfonodi regionali
		M0	metastasi assenti (categoria clinica)
		M1	≥ 1organi distanti o peritoneo
		M1a	1 organo distante
		M1b	≥ 1 organo distante
		M1c	peritoneo con o senza coinvolgimento di organi distanti

STADIO: I T1-T2 N0M0, II T3-T4 N0 M0, III N+ o N1c, IV M+







Fig. 6.18 Tubulovillous adenoma with invasive carcinoma. An ultra-low-power image of an example with high-grade dysplasia showing invasion into the smooth muscle in the head/neck region of the polyp by small clusters and single cells of adenocarcinoma.

pT1 Colorectal cancer (cancerized adenoma)


Histologic risk factors

Grading	G1,G2	G3,G4
Vascular invasion	no	yes
Resection margin	negative	positive
Budding	absent/low	high



Neither the Kikuchi (for sessile lesions) nor Haggitt (for polypoid tumors) are easy to use in practice. The depth and the width of invasion provides a more objective measure.

Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities



- CMS1-MSI immune subtype (~14%): characterized by MSI, CIMP high, diffuse immune infiltrate and BRAF V600E mutations; associated with worse survival after relapse.
- CMS2-canonical subtype (~37%): characterized by epithelial features, CIN, activated WNT and MYC signaling pathways;
- CMS3-metabolic subtype (~13%): characterized by deregulation of metabolic pathways, KRAS mutations, low level of CIMP and CIN, and mixed MSI status.
- CMS4-mesenchymal subtype (~23%): characterized by upregulation of EMT, TGF-β activation, angiogenesis, stromal infiltration; associated with worse relapse-free and overall survival.




Figure 1. Pie chart showing the frequency of colorectal carcinomas by histologic type.

Risk assessment models

(AJCC 2017, WHO 2018)

Twenty-nine prognostication tools for colorectal cancer were identified

- ❖ Age, sex, race, BMI, performance status
- ❖ Surgical procedure, treatment group
- ❖ Location of tumor
- ❖ Stage
- ❖ T category
- ❖ Number of lymph-nodes evaluated
- ❖ Number of lymph-nodes positive
- ❖ Lymph-nodes ratio
- ❖ Total mesorectal excision
- ❖ Complete mesocolon excision
- ❖ Grading
- ❖ Budding
- ❖ Lymphovascular invasion
- ❖ Perineural invasion
- ❖ Tumor Regression Grade
- ❖ Immune response
- ❖ MSI, KRAS, NRAS, BRAF

Digestive System Tumours

Edited by the WHO Classification of Tumours Editorial Board

